Table 5.

Analysis of factors associated with complete eradication of dysplasia in Barrett’s esophagus

Factor	Unadjusted analysis		Adjusted analysis
	OR (95% CI)	p-value	OR (95% CI)	p-value
Age (1 year increment)	0.96 (0.92, 1.01)	0.11	–	–
Male versus female gender	1.9 (0.68, 5.5)	0.22	–	–
Caucasian race	1.04 (0.12, 9.3)	0.97	–	–
Smoking
Ex-smoker versus non-smoker	0.91 (0.37, 2.2)	0.85	–	–
Current smoker versus non-smoker	0.64 (0.15, 2.7)	0.55	–	–
Current alcohol use	3.0 (1.1, 8.0)	0.027	–	–
Body mass index	1.01 (0.94, 1.08)	0.82	–	–
Aspirin	2.0 (0.83, 5.0)	0.12	–	–
NSAIDs	6.8 (0.86, 883.1)	0.2	–	–
Statins	1.2 (0.50, 2.7)	0.71	–	–
Proton pump inhibitors	1.6 (0.01, 30.4)	0.84	–	–
H2 blockers	0.04 (0.00, 0.49)	0.089	–	–
Hypertension	0.50 (0.20, 1.2)	0.14	–	–
Diabetes	0.70 (0.25, 2.0)	0.5	–	–
Hyperlipidemia	1.7 (0.70, 3.9)	0.26	–	–
History of fundoplication	0.29 (0.05, 1.8)	0.19	–	–
Length of Barrett’s segment (cm)	0.90 (0.80, 1.02)	0.092	–	–
Size of hiatal hernia (cm)	0.92 (0.73, 1.2)	0.46	–	–
Baseline biopsy
Cancer versus dysplasia	0.21 (0.08, 0.52)	< 0.001	0.24 (0.09, 0.63)	0.004
RFA versus cryotherapy	1.9 (0.78, 4.6)	0.16	1.7 (0.66, 4.3)	0.28
Num. of treatment sessions	1.04 (0.85, 1.3)	0.72	–	–
Months from baseline to last endoscopy (1 month increment)	1.03 (1.00, 1.05)	0.031	1.03 (1.00, 1.05)	0.039

CI confidence interval, NSAID nonsteroidal anti-inflammatory drugs, OR odds ratio, RFA radiofrequency ablation